Skyepharma PLC’s Chief Executive Appointed To Board

LONDON, April 5 /PRNewswire-FirstCall/ -- SkyePharma PLC announces that at a Board meeting yesterday its Chief Executive, Frank Condella, was appointed a Director of the Company. It was announced in February that Mr Condella, previously President of the European operations of IVAX prior to its acquisition by Teva in 2005, would become Chief Executive of SkyePharma and he took up this appointment on 1 March.

Frank Condella said: “I am pleased to be joining the Board. I have now completed my initial review of SkyePharma’s operations and I have been impressed by the Company’s employees, products and technologies. I look forward to working with my fellow directors to restructure our business and deliver sustainable profitability for the benefit of all shareholders.”

Dr Jerry Karabelas, SkyePharma’s Non-executive Chairman, said: “I am delighted to welcome Frank to the Board, where his long experience as a senior international manager in the pharmaceutical industry will provide us with valuable input. We are working together to implement the strategy we set in place earlier this year and I hope soon to be able to report to shareholders on progress.”

About SkyePharma

SkyePharma PLC develops pharmaceutical products benefiting from world- leading drug delivery technologies that provide easier-to-use and more effective drug formulations. There are now twelve approved products incorporating SkyePharma’s technologies in the areas of oral, injectable, inhaled and topical delivery, supported by advanced solubilisation capabilities. For more information, visit

Certain statements in this news release are forward-looking statements and are made in reliance on the safe harbour provisions of the U.S. Private Securities Litigation Act of 1995. Although SkyePharma believes that the expectations reflected in these forward-looking statements are reasonable, it can give no assurance that these expectations will materialize. Because the expectations are subject to risks and uncertainties, actual results may vary significantly from those expressed or implied by the forward-looking statements based upon a number of factors, which are described in SkyePharma’s 20-F and other documents on file with the SEC. Factors that could cause differences between actual results and those implied by the forward-looking statements contained in this news release include, without limitation, risks related to the development of new products, risks related to obtaining and maintaining regulatory approval for existing, new or expanded indications of existing and new products, risks related to SkyePharma’s ability to manufacture products on a large scale or at all, risks related to SkyePharma’s and its marketing partners’ ability to market products on a large scale to maintain or expand market share in the face of changes in customer requirements, competition and technological change, risks related to regulatory compliance, the risk of product liability claims, risks related to the ownership and use of intellectual property, and risks related to SkyePharma’s ability to manage growth. SkyePharma undertakes no obligation to revise or update any such forward-looking statement to reflect events or circumstances after the date of this release.

For further information please contact: SkyePharma PLC Frank Condella, Chief Executive +44 207 491 1777 Peter Laing, Director of Corporate Communications +44 207 491 5124 Sandra Haughton, US Investor Relations +1 212 753 5780 Buchanan Communications Tim Anderson / Mark Court / Rebecca Skye Dietrich +44 207 466 5000

SkyePharma PLC.

CONTACT: SkyePharma PLC, Frank Condella, Chief Executive, +44 207 4911777, Peter Laing, Director of Corporate Communications, +44 207 491 5124,Sandra Haughton, US Investor Relations, +1 212 753 5780, BuchananCommunications, Tim Anderson / Mark Court / Rebecca Skye Dietrich, +44 207466 5000